Biophysical Society Annual Meeting Satellite Meeting: Drug Discovery for Ion Channels XXV

Register

Dates & Times

14th February 2025

Location

Los Angeles, CA, USA

Organiser

Metrion, Sophion, Axxam and Nanion.

Event Details

Metrion have teamed up with Axxam, Nanion, SB Discovery and Sophion to deliver a series of presentations from drug discovery companies, companies that provide ion channel services to drug discovery companies and companies that provide products to ion channel drug discovery companies, as well as other speakers in the field of ion channel drug discovery, including several academic speakers.

Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases.  While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput.  Because of this, ion channels remain an underrepresented target class for drug discovery.

The advent of higher throughput automated electrophysiology systems changed the face of ion channel drug discovery.  Since the inaugural “Drug Discovery for Ion Channels” satellite meeting, there have been many advances in ion channel drug discovery including new instrumentation and techniques.  For this year, we propose to continue the “Satellite Meeting” tradition at the Biophysical Society Annual Meeting and review the advances ion channel drug discovery.

Event Agenda

08:00 Registration and coffee
08:30 Opening remarks Dr Chris Mathes, Metrion Biosciences
Session 1: Chaired by Daniel Sauter, Sophion Biosciences
08:45 Keynote To be announced
09:30 Diminazene Reveals Unexpected ASIC Biology John Gilchrist, Latigo Biotherapeutics
10:00 Subtype-Selective Modulation and Rescue of HCN1 Channel Mutants Jun Chen, Genentech
10:30 Coffee
Session 2: Chaired by Jean Francois Rolland, Axxam
11:00 Targeting Ion Channels with De Novo Designed Mini Proteins Stefan Pless, University of Copenhagen
11:30 Mining the Voltage-Gated Na+ Channel for Neurotherapeutics Development Fernanda Laezza, University of Texas
12:00 To be announced Jeremiah Osteen, Vertex Pharmaceuticals
12:30 Lunch
Session 3: Chaired by Niels Fertig, Nanion
13:30 Targeting AMPA Receptors in Complex with TARP-g8 for Epilepsy and Pain Jose Matta, Rapport Therapeutics
14:00 Targeting AMPA Receptors in Complex with TARP-g8 for Epilepsy and Pain Xi Huang, Toronto Hospital for Sick Children
14:30 To be announced Victoria Assimon, Maze Therapeutics
15:00 Coffee
Session 4: Chaired by Chris Mathes, Metrion Biosciences
15:30 To be announced Kris Kahlig, Praxis Precision Medicines
16:00 Reverse Use-Dependence of Nav1.8 Inhibitors GABA B Receptor Modulation of Membrane Excitability in Human Pluripotent Stem Cell-Derived Sensory Neurons by Baclofen and α-conotoxin Vc1.1 David Adams, University of Wollongong
16:30 To be announced Nina Ottossen, Linkoping University
17:00 Closing remarks Niels Fertig, Nanion
17:15 Close
Register
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram